China RNA Activation Venture Ractigen Looks To Clinic For Validation

 
• By Dexter Jie Yan

A China returnee CEO has raised roughly $50m for his bioventure that is looking to clinically validate and commercialize an RNA activation platform he co-discovered while working in the US.

hitting the on switch
Ractigen races to hit on switch after raising $50m since 2017 foundation • Source: Shutterstock

More from China

More from Focus On Asia